Interview with Hoon Han, President, Histostem
After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone…
Address: Seongnam jungwongu beltway 210 (sangdaewondong) 101
Tel: (031)-732-1555
Web: http://www.seoulcord.co.kr/index1.asp
Histostem is a stem cell provider, specializing in the MLPCs (Multi-Lineage Progenitor Cells) research, the treatment of disease and injury, and the banking of stem cells. Stem cells are the body’s “master” cells because they give rise to all other tissues, organs, and systems in the body. The stemcells’ ability to differentiate, or change, into other types of cells in the body, is a fairly new discovery that holds tremendous promise for treating and curing some of the most common diseases such as heart diseases, cancers, stroke, paralysis, liver cirrhosis, Buerger’s and Alzheimer’s diseases. What’s more, this treatment is not years away. Histostem is already using hematopoietic stemcells taken from UCB to treat blood diseases such as various kinds of leukemia, multiple sclerosis, amyotrophic lateral sclerosis, etc. Histostem also succeeded in extracting non-hematopoietic multipotent stem cells from UCB in their most pure state and perfected in multiplying and cultivating those stemcells. Histostem is the world’s first runner in applying our stem cell therapy to human patients, and currently using our stem cells to treat with great success such illnesses as Buerger’s disease, Type II diabetes, liver cirrhosis, paralysis after spinal cord injury, osteoporosis, chronic renal failure, and Alzheimer’s disease, to name a few. Finally, in order to achieve the most effective donor matching of cord blood to patient, our research technicians are busy typing the human leukocyte antigens (HLA) in our biogenetics laboratory.
Stem cell provider, specializing in the MLPCs (Multi-Lineage Progenitor Cells) research, the treatment of disease and injury, and the banking of stem cells.
After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone…
Oh Pil-Soo, managing director of Lundbeck Korea, talks about the challenges of pricing and reimbursement in the CNS area and remaining committed to Korea in terms of clinical research. …
Brian Gladsden was appointed president of Novartis Korea in January 2014. He relates his previous experience to the market situation in Korea and highlights the importance of commitment to innovation…
The American Chamber of Commerce in Korea (Amcham Korea) was established in 1953 and has a long history in developing bilateral economic and trade relations between the US and Korea. Amy…
Cho Chan-Hwui, president of the Korean Pharmaceutical Association (KPA), discusses the major hurdles that pharmacists in Korea must overcome today, and the increased focus on prescription by INN. How…
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
Dr. Jung Yun-Taek, head researcher of the pharmaceutical division at the Korea Health Industry Development Institute (KHIDI), discusses the real potential that Korean pharmaceutical companies offer to the rest of…
The European Chamber of Commerce in Korea (ECCK) was founded in 2012, in order to represent the interests of European businesses in Korea. Christoph Heider, secretary general of ECCK, discusses…
Yuhan is one of the largest and fastest growing pharmaceutical companies in South Korea, with a long history in the sector. In your view, what are the main elements that…
South Korea has a much shorter history of clinical trials than many other advanced economies. In your view, what is the potential for South Korea’s clinical trial industry today? The…
After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone…
Could you provide our international readers with a profile of Bioneer as it stands today? Bioneer, having a strong basis of technology and experiences in molecular biology since 1992, we…
Although Chungcheongbuk-do is a small province in terms of territory and population, it has gained increasing importance in Korea’s economy. What are the main drivers of this growing economic progression?…
See our Cookie Privacy Policy Here
